

Investigation of the Effects of Moxifloxacin  
on Human Neutrophils and Mononuclear  
Leucocytes *in vitro*

by

Moliehi Potjo

Submitted in fulfillment for the degree of Master of Science (MSc)

in

The Department of Immunology  
Faculty of Health Sciences  
University of Pretoria

March 2007

**DECLARATION**

I declare that the work contained in this dissertation is my original work and has not been presented for a degree in any other institution. It is being submitted in fulfilment for the MSc degree at the University of Pretoria.

Signed: \_\_\_\_\_

Date: \_\_\_\_\_

## ACKNOWLEDGEMENTS

First and foremost I want to thank the Almighty for the strength, courage and wisdom He has given me till this point of my academic life.

This dissertation is by far most significant scientific accomplishment in my life and would be impossible without the people who supported and believed in me.

My supervisor: Professor Ronald Anderson, Head, Department of Immunology, University of Pretoria, who gave me the opportunity to do this research and generously gave of his expertise and time.

My co-supervisor: Professor Annette Theron, Department of Immunology, University of Pretoria, for her invaluable guidance, encouragement and support.

Last, but not least, I want to express appreciation for the assistance received from the following with guidance and advice in respect of the laboratory work and preparation of this manuscript: Dr Helen Steel, Dr Riana Cockeran and Mrs Joyce Oommen.

Not to forget my beloved family for their unconditional love and trust they always had in me.

## SUMMARY

Moxifloxacin is considered to be a broad-spectrum fluoroquinolone due to its activity against both gram positive and gram negative bacteria. Importantly this agent is currently being evaluated in ongoing clinical trials in South Africa and South America as a treatment for pulmonary tuberculosis, with the specific objective of decreasing the duration of chemotherapy. However, relatively little is known about the effects of moxifloxacin on host defenses, particularly innate protective mechanisms, involving neutrophils.

The primary theme of the laboratory research presented in this dissertation was to investigate the role of moxifloxacin in modulating the host immune system, specifically neutrophil protective functions, as well as lymphocyte proliferation and cytokine production (IL-1 $\beta$ , IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL13, IL-17, IFN- $\gamma$ , GM-CSF, G-CSF, TNF- $\alpha$ , and MCP-1).

The generation of reactive oxidants and elastase release by neutrophils activated with the chemoattractant, fMLP, or the phorbol ester, PMA, were assayed using luminol- and lucigenin-enhanced chemiluminescence (LECL) and colorimetric procedures, while alterations in cytosolic Ca<sup>2+</sup> concentrations were monitored by radiometric (<sup>45</sup>Ca<sup>2+</sup>) procedures. Moxifloxacin (1-20  $\mu$ g/ml) was found to have no significant priming or inhibitory effects on oxidant generation by human neutrophils activated with fMLP or PMA, while elastase release was increased at the highest concentrations of the antibiotic. The magnitude of efflux or store-operated Ca<sup>2+</sup> influx was unaffected following activation of neutrophils with fMLP.

Moxifloxacin at all concentrations tested, did not affect either lymphocyte proliferation or CD25 expression by PHA-activated mononuclear leukocytes (MNLs). Similarly, none of the cytokines measured were significantly affected by moxifloxacin, either in the absence or presence of PHA, compatible with a lack of effect of this agent on Th1 and Th2 lymphocytes.

In conclusion, this study suggests that moxifloxacin, at therapeutic doses, does not affect the protective functions of human neutrophils and lymphocytes.

## SAMEVATTING

Moksifloksasin word beskou as 'n breë spektrum fluoroquinoloon met aktiwiteit teen beide gram positiewe en gram negatiewe bakterieë. Dit is noemenswaardig dat hierdie agent tans in kliniese proewe in Suid Afrika en Suid Amerika getoets word as behandeling vir pulmonêre tuberkulose, met die spesifieke doel om die duur van chemoterapie te verminder. Daar is egter relatief min bekend oor die uitwerking van moksifloksasin op gasheerverdediging, veral intrinsieke beskermende meganismes soos neutrofiele.

Die hooftema van die laboratorium navorsing wat in hierdie verhandeling aangebied word, is om die rol van moksifloksasin in die modulering van die gasheer immuunsisteem te ondersoek veral met betrekking tot neutrofiel beskermende funksies, sowel as limfosiet proliferasie en sitokien produksie (IL-1 $\beta$ , IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-17, IFN- $\gamma$ , GM-CSF, G-CSF, TNF- $\alpha$  and MCP-1).

Die produksie van reaktiewe oksidante en vrystelling van elastase deur neutrofiele, geaktiveer deur die leukolokmiddel, fMLP, of die forbol ester, PMA, is getoets deur gebruik te maak van luminol- en lusigenin-verhoogde chemiluminessensie en kolorimetriese prosedures. Veranderinge in sitosoliese Ca<sup>2+</sup> konsentrasies is gemeet met behulp van radiometriese (<sup>45</sup>Ca<sup>2+</sup>) prosedures. Moksifloksasin (1-20 $\mu$ g/ml) het nie 'n betekenisvolle sensitiserende of inhiberende uitwerking op oksidant generasie van mens neutrofiele geaktiveer met fMLP of PMA gehad nie terwyl elastase vrystelling verhoog is by die hoogste konsentrasies van die antibiotika. Moksifloksasin het ook nie die effluks of stoor-operatiewe Ca<sup>2+</sup> influks in neutrofiele geaktiveer met fMLP, geaffekteer nie.

Moksifloksasin het by alle konsentrasies getoets, nie limfosiet proliferasie of CD25 uitdrukking deur PHA-geaktiveerde mononukleêre leukosiete, geaffekteer nie. Eweneens is geen van die sitokiene gemeet, betekenisvol geaffekteer deur moksifloksasin in die afwesigheid of teenwoordigheid van PHA nie. Hierdie resultaat toon dat die antibiotika nie 'n effek op Th1 en Th2 limfosiete het nie.

Ten slotte, dui die studie aan dat mokifloksasin by terapeutiese dosisse geen uitwerking op die produktiewe funksies van mens neutrofiële en T-limfosiete het nie.

## TABLE OF CONTENTS

	<b>Page</b>
<b>Acknowledgements</b>	<b>ii</b>
<b>Summary</b>	<b>iii</b>
<b>Table of contents</b>	<b>vii</b>
<b>List of figures</b>	<b>xi</b>
<b>List of tables</b>	<b>xiii</b>
<b>List of abbreviations</b>	<b>xiv</b>
<b>CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW</b>	
1.1 INTRODUCTION	1
1.2 LITERATURE REVIEW	3
1.2.1 History of Quinolones	3
1.2.2 Moxifloxacin structure and functions	4
1.3 Phamacology	5
1.3.1 Metabolism	5
1.3.2 Mechanism of action	6
1.3.3 Resistance	7
1.4 Inflammation	9
1.4.1 Leukocyte entry into sites of inflammation	9
1.5 Neutrophils	12
1.5.1 Cytoplasmic granules	13
1.5.1.1 Primary granules	13
1.5.1.2 Secondary granules	14
1.5.1.3 Tertiary and secretory granules	14
1.5.2 Neutrophil elastase	15



1.6 Antimicrobial mechanisms of neutrophils	16
1.6.1 NADPH oxidase	17
1.6.2 NADPH oxidase activation	17
1.7 Respiratory bust of human neutrophils	19
1.8 Nitric oxide synthase	21
1.9 Calcium and neutrophil activation	21
1.9.1 Calcium fluxes and restoration of Ca <sup>2+</sup> homeostasis in Activated neutrophils	21
1.9.2 Ca <sup>2+</sup> release from stores	22
1.9.3 Restoration of Ca <sup>2+</sup> homeostasis	23
1.10 Interaction of pore forming pneumolysin with neutrophils	25
1.11 Lymphocyte development and heterogeneity	25
1.12 CD4 and CD8 T-cell functions	27
1.13 Helper T-lymphocytes	27
1.14 Antigen processing and presentation to T-cells	28
1.15 Antigen recognition by T-cells	31
1.16 T-cell activation	32
1.17 T lymphocyte proliferation	33
1.18 IL-2 receptor structure and composition	36
1.19 Properties and functions of cytokines	37
1.19.1 Anti-inflammatory cytokines	38

1.20 Chemokines	40
-----------------	----

## **CHAPTER 2: HYPOTHESIS AND OBJECTIVES**

2.1 Hypothesis	42
----------------	----

2.2 Objectives	42
----------------	----

## **CHAPTER 3: EFFECTS OF MOXIFLOXACIN ON HUMAN NEUTROPHIL FUNCTIONS**

3.1 INTRODUCTION	44
------------------	----

3.2 MATERIALS AND METHODS	44
---------------------------	----

3.2.1 Reagents	44
----------------	----

3.2.2 Neutrophil isolation	44
----------------------------	----

3.2.3 Oxidant generation	45
--------------------------	----

3.2.4 Elastase release	45
------------------------	----

3.2.5 Radiometric assessment of Ca <sup>2+</sup> fluxes	46
---	----

3.2.5.1 Influx of <sup>45</sup> Ca <sup>2+</sup> into moxifloxacin-treated neutrophils	46
--	----

3.2.5.2 Efflux of <sup>45</sup> Ca <sup>2+</sup> from moxifloxacin-treated neutrophils	47
--	----

3.2.6 Cellular ATP levels	47
---------------------------	----

3.2.7 Statistical analysis	48
----------------------------	----

3.3 RESULTS	48
-------------	----

3.3.1 Effects of moxifloxacin on luminol- and lucigenin-enhanced chemiluminescence responses of fMLP- and PMA-activated neutrophils	48
---	----

3.3.2 Effects of moxifloxacin on elastase release by fMLP/CB-activated neutrophils	49
--	----

3.3.3 Effects of moxifloxacin on ATP levels as an index of viability	49
3.3.4 Effects of moxifloxacin on Ca <sup>2+</sup> fluxes	49
3.3.4.1 Effects on influx of <sup>45</sup> Ca <sup>2+</sup>	49
3.3.4.2 Effects on efflux of <sup>45</sup> Ca <sup>2+</sup>	50
3.4 DISCUSSION	56
<b>CHAPTER 4: EFFECTS OF MOXIFLOXACIN ON PHA-ACTIVATED HUMAN MONONUCLEAR LEUKOCYTES</b>	
4.1 INTRODUCTION	60
4.2 MATERIALS AND METHODS	60
4.2.1 Reagents	60
4.2.2 Isolation of Mononuclear leukocytes	60
4.2.3 Lymphocyte proliferation assay	61
4.2.4 CD25 expression by PHA-activated T lymphocytes	61
4.2.5 Cytokine production by PHA-activated mononuclear leukocytes	62
4.2.6 Statistical analysis	63
4.3 RESULTS	63
4.3.1 Effects of moxifloxacin on lymphocyte proliferation and expression of CD25	63
4.3.2 Effects of moxifloxacin on cytokine production by PHA-activated mononuclear leukocytes	64
4.4 DISCUSSION	72

<b>CHAPTER 5: GENERAL CONCLUSION</b>	75
--------------------------------------	----

<b>CHAPTER 6: REFERENCES</b>	76
------------------------------	----

**LIST OF FIGURES**

	<b>Page</b>
<b>Figure 1.1:</b> Chemical structure of moxifloxacin	5
<b>Figure 1.2:</b> Fluoroquinolone mechanism of action	8
<b>Figure 1.3:</b> Leukocyte recruitment to the site of inflammation	11
<b>Figure 1.4:</b> Activation of NADPH oxidase	19
<b>Figure 1.5:</b> Release of Ca <sup>2+</sup> from intracellular stores and clearance of cytosolic Ca <sup>2+</sup> in fMLP- activated human neutrophils	24
<b>Figure 1.6:</b> Antigen processing and presentation to T lymphocytes	31
<b>Figure 1.7:</b> T-cell proliferation	35
<b>Figure 3.1:</b> Effects of moxifloxacin on the release of elastase by fMLP/CB-activated neutrophils	55
<b>Figure 4.1:</b> Effects of moxifloxacin on PHA-activated lymphocyte proliferation	65
<b>Figure 4.2:</b> Effects of moxifloxacin on CD25 expression by PHA-activated mononuclear leukocytes	66
<b>Figure 4.3:</b> Effects of moxifloxacin on IL-6 production by PHA-activated mononuclear leukocytes	68

**Figure 4.4:** Effects of moxifloxacin on IL-12 production by PHA-activated mononuclear leukocytes

69

## LIST OF TABLES

	<b>Page</b>
<b>Table 1.1:</b> Major human cytokines	39
<b>Table 1.2:</b> Common chemokines	41
<b>Table 3.1a:</b> Effects of moxifloxacin on lucigenin-enhanced chemiluminescence superoxide production by fMLP-activated neutrophils	51
<b>Table 3.1b:</b> Effects of moxifloxacin on lucigenin-enhanced chemiluminescence superoxide production by PMA-activated neutrophils	52
<b>Table 3.2a:</b> Effects of moxifloxacin on luminol-enhanced chemiluminescence oxidant production by fMLP-activated neutrophils	53
<b>Table 3.2b:</b> Effects of moxifloxacin on luminol-enhanced chemiluminescence oxidant production by PMA-activated neutrophils	54
<b>Table 4.1:</b> Effects of moxifloxacin on IL-6 and IL-12 production by PHA-activated mononuclear cells	67
<b>Table 4.2:</b> Effects of moxifloxacin on cytokine production by PHA-activated mononuclear cells	70

## LIST OF ABBREVIATIONS

Ab	Antibody
Ag	Antigen
ANOVA	Analysis of variance
APCs	Antigen presenting cells
ATP	Adenosine 3', 5-triphosphate
Ca <sup>2+</sup>	Calcium ion
[Ca <sup>2+</sup> ] <sub>i</sub>	Concentration of intracellular calcium
<sup>45</sup> Ca <sup>2+</sup>	Calcium-45 chloride
Ca <sup>2+</sup> -ATPase	Calcium-adenosine 3', 5'-triphosphatase
CaCl <sub>2</sub>	Calcium chloride
CB	Cytochalasin B
CD	Cluster of differentiation
CG	Cathepsin
CGD	Chronic granulomatous disease
Cl <sup>-</sup>	Chloride ion
CSF	Colony stimulating factor
CTL	Cytotoxic T lymphocyte
DMSO	Dimethyl sulphoxide
EGTA	Ethylene glycol-bis (beta-amino-ethyl-ether)-N, N, N', N'- tetraacetic acid
ER	Endoplasmic reticulum
FCS	Fetal calf serum
Fe <sup>2+</sup>	Ferrous ion
Fe <sup>3+</sup>	Ferric ion
FITC	Fluorescein isothiocyanate
FMLP	N-formyl-L-methionyl-L-leucyl-L-phenylalanine
GM-CSF	Granulocyte/macrophage colony stimulating factor
GTP	Guanosine triphosphate
H <sup>+</sup>	Proton
<sup>3</sup> H	Thymidine (tritiated)
HBSS	Hanks' balanced salt solution
HLA	Human histocompatibility leukocyte antigen



H <sub>2</sub> O <sub>2</sub>	Hydrogen peroxide
HOCL	Hypochlorous acid
IFN	Interferon
Ig	Immunoglobulin
IL	Interleukin
iNOS	Induced nitric oxide synthase
IP <sub>3</sub>	Inositoll, 4,5-triphosphate
IP <sub>3</sub> -ICR	IP <sub>3</sub> -induced Ca <sup>2+</sup> release
iPLA <sub>2</sub>	Ca <sup>2+</sup> -intended phospholipase A <sub>2</sub>
IP <sub>3</sub> ROC	IP <sub>3</sub> receptor-operated channel
KDa	kiloDalton
Licigenin	bis-N-methylacridinium nitrate
Luminol	5-amino-2,5-dihydro-1,4-phthalazinedione
LECL	Lucigenin-enhanced chemiluminescence
LPA	Lymphocyte proliferation assay
LPS	Lipopolysaccharide
mAb	Monoclonal antibody
MCP-1	Monocyte chemotactic protein-1
MHC	Major histocompatibility complex
MPO	Myeloperoxidase
NADPH	Nicotinamide adenine dinucleotide phosphate (reduced form)
NADP <sup>+</sup>	Nicotinamide adenine dinucleotide phosphate (oxidized form)
NaOH	Sodium hydroxide
NE	Neutrophil elastase
NF- <sub>k</sub> B	Nuclear transcription factor-kappa B
NH <sub>4</sub> Cl	Ammonium chloride
NO	Nitric oxide
NRS	Nucleotide releasing substrate
O <sub>2</sub>	Oxygen
O <sub>2</sub> <sup>-</sup>	Superoxide anion
<sup>1</sup> O <sub>2</sub>	Singlet oxygen
.OH/HO <sup>-</sup>	Hydroxyl radical
p22 <sup>phox</sup>	Protein/polypeptide phagocyte oxidase, 22kDa molecular weight

PBS	Phosphate-buffer saline
PHA	Phytohaemagglutinin
PMA	Phorbol-12-myristate 13-acetate
PMNL	Polymorphonuclear leukocyte
Rho-GDI	Guanosine nucleotide dissociation inhibitor
RIA	Radioimmunoassay
ROCC	Receptor-operated $Ca^{2+}$ channel
ROI	Reactive oxygen intermediate
ROS	Reactive oxygen species
SEM	Standard error of the mean
SER	Sarco-endoplasmic reticulum
SERCA	Sarco-endoplasmic reticulum $Ca^{2+}$ -ATPase
SNF	Supernatant fluid
SOC	Store operated channel
SOCC	Store-operated calcium channels
SOCE	Store-operated $Ca^{2+}$ entry
SOD	Superoxide dismutase
TCR	T-cell receptor
Th	T helper cell
TNF- $\alpha$	Tumor necrosis factor alpha
TRPC	Transient receptor potential channel
VGCC	Voltage-gated $Ca^{2+}$ channels CIF - $Ca^{2+}$ influx factor